✦ LIBER ✦

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

✍ Scribed by Peter Hillmen; Dena R. Cohen; Kim Cocks; Andrew Pettitt; Hazem A. Sayala; Andy C. Rawstron; Daniel B. Kennedy; Christopher Fegan; Don W. Milligan; John Radford; Jane Mercieca; Claire Dearden; Raphael Ezekwisili; Alexandra F. Smith; Julia Brown; Gillian A. Booth; Abraham M. Varghese; Christopher Pocock; on behalf of NCRI CLL Sub-Group

Book ID: 108676906
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 187 KB
Volume: 152
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2010.08317.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of the histone deacetylas

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

✍ Kristie A. Blum; Anjani Advani; Louis Fernandez; Richard Van Der Jagt; Joseph Br 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO